Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Harefuah
|
February 23, 2022
[GENOMIC PROFILING IN LUMINAL BREAST CANCER]
Ari Raphael, Amir Sonnenblick
NPJ Systems Biology and Applications
|
August 8, 2025
Breast cancer is detectable from peripheral blood using machine learning over T cell receptor repertoires
Miriam Zuckerbrot-Schuldenfrei, Ari Raphael, Alona Zilberberg, et al.
BMC Medical Research Methodology
|
January 8, 2022
Oncologic patients' misconceptions may impede enrollment into clinical trials: a cross-sectional study
Nethanel Asher, Ari Raphael, Ido Wolf, et al.
Breast Cancer Research and Treatment
|
April 7, 2024
Body composition measures as a determinant of Alpelisib related toxicity
Eliya Shachar, Ari Raphael, Uriel Katz, et al.
Genes
|
October 27, 2022
Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
Ari Raphael, Mali Salmon-Divon, Jessica Epstein, et al.
JCO Oncology Practice
|
March 25, 2026
Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non-Small Cell Lung Cancer: Insights From a National Real-World Cohort
Eliya Shachar, Uriel Katz, Shir Barilier, et al.
Journal of Clinical Medicine
|
March 17, 2025
Real-World Data on Osimertinib-Associated Cardiac Toxicity
Abed Agbarya, Ari Raphael, Hadas Gantz Sorotsky, et al.
Life (Basel, Switzerland)
|
August 26, 2022
Valvular Heart Disease following Anthracycline Therapy-Is It Time to Look beyond Ejection Fraction?
David Zahler, Joshua H Arnold, Tali Bar-On, et al.
Clinical Cardiology
|
January 20, 2023
High neutrophil-to-lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracycline
Ranny Baruch, David Zahler, Lior Zornitzki, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter Study
Itamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Harefuah
|
February 23, 2022
[GENOMIC PROFILING IN LUMINAL BREAST CANCER]
Ari Raphael, Amir Sonnenblick
NPJ Systems Biology and Applications
|
August 8, 2025
Breast cancer is detectable from peripheral blood using machine learning over T cell receptor repertoires
Miriam Zuckerbrot-Schuldenfrei, Ari Raphael, Alona Zilberberg, et al.
BMC Medical Research Methodology
|
January 8, 2022
Oncologic patients' misconceptions may impede enrollment into clinical trials: a cross-sectional study
Nethanel Asher, Ari Raphael, Ido Wolf, et al.
Breast Cancer Research and Treatment
|
April 7, 2024
Body composition measures as a determinant of Alpelisib related toxicity
Eliya Shachar, Ari Raphael, Uriel Katz, et al.
Genes
|
October 27, 2022
Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
Ari Raphael, Mali Salmon-Divon, Jessica Epstein, et al.
JCO Oncology Practice
|
March 25, 2026
Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non-Small Cell Lung Cancer: Insights From a National Real-World Cohort
Eliya Shachar, Uriel Katz, Shir Barilier, et al.
Journal of Clinical Medicine
|
March 17, 2025
Real-World Data on Osimertinib-Associated Cardiac Toxicity
Abed Agbarya, Ari Raphael, Hadas Gantz Sorotsky, et al.
Life (Basel, Switzerland)
|
August 26, 2022
Valvular Heart Disease following Anthracycline Therapy-Is It Time to Look beyond Ejection Fraction?
David Zahler, Joshua H Arnold, Tali Bar-On, et al.
Clinical Cardiology
|
January 20, 2023
High neutrophil-to-lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracycline
Ranny Baruch, David Zahler, Lior Zornitzki, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter Study
Itamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.
Page
of 2